Effettuare il login Iscriviti gratis

Cellectis Est. Q/Q di EPS

Cos'è Est. Q/Q di EPS di Cellectis?

Est. Q/Q di EPS di Cellectis è -45.12%

Qual è la definizione di Est. Q/Q di EPS?



Il tasso di crescita prospettico trimestrale dell'utile, anno su anno , è l'aumento stimato di EPS di una società per il prossimo trimestre rispetto alla performance di un trimestre precedente.

The prospective EPS growth rate is a predicted estimate of the earnings per share growth rate towards the current quarter and expressed as a percentage compared to the respective past quarter. The estimated earnings per share growth rate is an important factor for judging a company's value. Comparing EPS history with stock price history helps determine the most likely future direction of the stock price.

Earnings per share is the monetary value of earnings per outstanding share of common stock for a company. The EPS is usually calculated as profit without preferred dividends divided by weighted average of common stock shares over the past twelve months.

Est. Q/Q di EPS di aziende nel Health Care settore su NASDAQ rispetto a Cellectis

Cosa fa Cellectis?

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.

Aziende con est. q/q di eps simili a Cellectis